JPS6323817A - ブロモクリプチンの新用途 - Google Patents
ブロモクリプチンの新用途Info
- Publication number
- JPS6323817A JPS6323817A JP62174576A JP17457687A JPS6323817A JP S6323817 A JPS6323817 A JP S6323817A JP 62174576 A JP62174576 A JP 62174576A JP 17457687 A JP17457687 A JP 17457687A JP S6323817 A JPS6323817 A JP S6323817A
- Authority
- JP
- Japan
- Prior art keywords
- bromocriptine
- disease
- treatment
- diabetes mellitus
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 title claims description 46
- 229960002802 bromocriptine Drugs 0.000 title claims description 44
- 238000011282 treatment Methods 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 230000001363 autoimmune Effects 0.000 claims description 13
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 12
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 206010028417 myasthenia gravis Diseases 0.000 claims description 9
- 208000019838 Blood disease Diseases 0.000 claims description 8
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 8
- 208000014951 hematologic disease Diseases 0.000 claims description 8
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 8
- 230000002124 endocrine Effects 0.000 claims description 7
- 208000030533 eye disease Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 208000023328 Basedow disease Diseases 0.000 claims description 6
- 208000015023 Graves' disease Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 1
- 238000002474 experimental method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000009467 reduction Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 201000001474 proteinuria Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 102000003946 Prolactin Human genes 0.000 description 4
- 108010057464 Prolactin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 229940097325 prolactin Drugs 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 208000007475 hemolytic anemia Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003172 anti-dna Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002449 erythroblastic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940000596 parlodel Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- -1 methanesulfonic acid Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88511086A | 1986-07-14 | 1986-07-14 | |
| US885110 | 1986-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6323817A true JPS6323817A (ja) | 1988-02-01 |
Family
ID=25386156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62174576A Pending JPS6323817A (ja) | 1986-07-14 | 1987-07-13 | ブロモクリプチンの新用途 |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS6323817A (fr) |
| KR (1) | KR880001292A (fr) |
| AU (1) | AU602154B2 (fr) |
| CH (1) | CH672987A5 (fr) |
| DE (1) | DE3722383A1 (fr) |
| DK (1) | DK363887A (fr) |
| FR (1) | FR2601245A1 (fr) |
| GB (1) | GB2192541B (fr) |
| IT (1) | IT1224222B (fr) |
| NL (1) | NL8701631A (fr) |
| PH (1) | PH24525A (fr) |
| SE (1) | SE8702843L (fr) |
| ZA (1) | ZA875145B (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0748257A (ja) * | 1990-01-10 | 1995-02-21 | Univ Louisiana State | 第ｉｉ型糖尿病治療薬 |
| JP2009046504A (ja) * | 1994-07-07 | 2009-03-05 | General Hospital Corp Dba Massachusetts General Hospital | 免疫機能調整のためのプロラクチン減少剤及び／又は増強剤の使用 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3814521A1 (de) * | 1987-05-07 | 1988-11-17 | Sandoz Ag | Neue anwendung von dopaminrezeptor-agonisten |
| EP0327040A3 (fr) * | 1988-02-05 | 1990-11-28 | Predrag Dr.Sc. Sikiric | Utilisation de la dopamine et/ou d'agonistes dopaminergiques pour la préparation de médicaments pour le traitement du tractus digestif |
| US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US5830895A (en) * | 1988-05-10 | 1998-11-03 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for the determination and adjustment of prolactin daily rhythms |
| US6004972A (en) * | 1988-05-10 | 1999-12-21 | The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5744477A (en) * | 1988-05-10 | 1998-04-28 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for treatment of obesity using prolactin modulators and diet |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5716932A (en) * | 1988-05-10 | 1998-02-10 | Louisiana State University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates |
| US5668155A (en) * | 1988-05-10 | 1997-09-16 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| US5585347A (en) * | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
| US5700800A (en) * | 1988-05-10 | 1997-12-23 | Ergo Science Incorporated | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound |
| CZ282909B6 (cs) * | 1991-12-23 | 1997-11-12 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Použití agonisty dopaminu a stimulátoru prolaktinu pro přípravu farmaceutického přípravku a tento farmaceutický přípravek |
| IL112106A0 (en) * | 1993-12-22 | 1995-03-15 | Ergo Science Inc | Accelerated release composition containing bromocriptine |
| US5626860A (en) * | 1995-06-07 | 1997-05-06 | The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College | Method for regulating metabolism with dopamine beta hydroxylase inhibitors |
| US5714519A (en) * | 1995-06-07 | 1998-02-03 | Ergo Science Incorporated | Method for regulating glucose metabolism |
| US20010016582A1 (en) | 1997-04-28 | 2001-08-23 | Anthony H. Cincotta | Method and composition for the treatment of lipid and glucose metabolism disorders |
| US20090325997A1 (en) * | 2006-11-23 | 2009-12-31 | Ergonex Pharma Gmbh | Pharmaceutical Compositions For The Treatment Of Capillary Arteriopathy |
| HRP20211488T1 (hr) * | 2016-04-20 | 2022-02-18 | Veroscience Llc | Sastav i metoda za liječenje metaboličkih poremećaja |
| AU2018351131B2 (en) | 2017-10-18 | 2024-05-30 | Veroscience Llc | Improved bromocriptine formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| CH666406A5 (de) * | 1984-02-29 | 1988-07-29 | Sandoz Ag | Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten. |
| GB2154874B (en) * | 1984-02-29 | 1987-11-04 | Sandoz Ltd | Bromoscriptine compositions |
-
1987
- 1987-07-07 DE DE19873722383 patent/DE3722383A1/de not_active Withdrawn
- 1987-07-09 CH CH2611/87A patent/CH672987A5/de not_active IP Right Cessation
- 1987-07-10 FR FR8709849A patent/FR2601245A1/fr not_active Withdrawn
- 1987-07-10 IT IT48160/87A patent/IT1224222B/it active
- 1987-07-10 GB GB8716323A patent/GB2192541B/en not_active Expired - Lifetime
- 1987-07-10 NL NL8701631A patent/NL8701631A/nl not_active Application Discontinuation
- 1987-07-13 DK DK363887A patent/DK363887A/da not_active Application Discontinuation
- 1987-07-13 AU AU75587/87A patent/AU602154B2/en not_active Ceased
- 1987-07-13 JP JP62174576A patent/JPS6323817A/ja active Pending
- 1987-07-13 KR KR1019870007490A patent/KR880001292A/ko not_active Application Discontinuation
- 1987-07-13 SE SE8702843A patent/SE8702843L/ not_active Application Discontinuation
- 1987-07-14 PH PH35534A patent/PH24525A/en unknown
- 1987-07-14 ZA ZA875145A patent/ZA875145B/xx unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0748257A (ja) * | 1990-01-10 | 1995-02-21 | Univ Louisiana State | 第ｉｉ型糖尿病治療薬 |
| JP2009046504A (ja) * | 1994-07-07 | 2009-03-05 | General Hospital Corp Dba Massachusetts General Hospital | 免疫機能調整のためのプロラクチン減少剤及び／又は増強剤の使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1224222B (it) | 1990-09-26 |
| GB2192541A (en) | 1988-01-20 |
| NL8701631A (nl) | 1988-02-01 |
| DK363887D0 (da) | 1987-07-13 |
| PH24525A (en) | 1990-07-18 |
| GB8716323D0 (en) | 1987-08-19 |
| DE3722383A1 (de) | 1988-01-28 |
| GB2192541B (en) | 1990-05-02 |
| AU602154B2 (en) | 1990-10-04 |
| FR2601245A1 (fr) | 1988-01-15 |
| DK363887A (da) | 1988-01-15 |
| KR880001292A (ko) | 1988-04-22 |
| IT8748160A0 (it) | 1987-07-10 |
| SE8702843L (sv) | 1988-01-15 |
| SE8702843D0 (sv) | 1987-07-13 |
| CH672987A5 (fr) | 1990-01-31 |
| ZA875145B (en) | 1989-02-22 |
| AU7558787A (en) | 1988-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6323817A (ja) | ブロモクリプチンの新用途 | |
| US7723290B2 (en) | Compositions and methods for modulating the immune system | |
| US20200101042A1 (en) | 4-methylumbelliferone treatment for immune modulation | |
| Fairburn et al. | Anorexia nervosa in diabetes mellitus. | |
| Elliott et al. | An abnormal insulin in juvenile diabetes mellitus | |
| EP0170623A2 (fr) | Emploi pharmaceutique de (NVA)2-cyclosporine | |
| JP2527749B2 (ja) | 移植拒否反応抑制または自己免疫疾患治療用薬学的組成物 | |
| AU746210B2 (en) | Histone containing composition to treat rheumatoid arthritis | |
| Ridolfo et al. | Clinical Experiences with Carbutamide, an Orally Given Hypoglycemic Agent: Preliminary Report | |
| RU2077882C1 (ru) | Иммуномодулирующее средство | |
| PICHEL WARNER | Hyperserotoninemia in functional gastrointestinal disease | |
| JP2002003391A (ja) | エゾウコギを用いた薬剤並びに組成物及びその抽出方法 | |
| WO2022052016A1 (fr) | Compositions pharmaceutiques et leurs utilisations dans le traitement de la maladie de parkinson | |
| KR20220063762A (ko) | 배암차즈기 추출물을 포함하는 스트레스 개선용 건강기능식품 | |
| Hintze et al. | A case of valproate intoxication with excessive brain edema | |
| JPH07506568A (ja) | 糖尿病治療のための既存の薬剤の使用 | |
| Heikinheimo | Severe prolonged hypoglycemia following tolbutamide and carbutamide treatment | |
| US20030007964A1 (en) | Method for treating rheumatoid arthritis with composition containing histone | |
| US20230151073A1 (en) | Fibrillation resistant calcitonin peptides and uses thereof | |
| US3475534A (en) | Methods of treating hyperinsulinism | |
| JPH0361651B2 (fr) | ||
| JPH0826987A (ja) | アシルカルニチン含有製剤 | |
| WO2020240550A1 (fr) | Cannabidiol pour le traitement de diabète sucré de type 1 | |
| McGavack et al. | Extreme insulin resistance: a case study | |
| Garg et al. | Teplizumab: a new glimmer of hope for type 1 diabetic patients |